| Literature DB >> 21516572 |
Abstract
A method is proposed for modifying a group-sequential clinical trial by restricting future enrollment to a subgroup and possibly altering the sample size of the subgroup, based on an interim analysis of the data already obtained. The method provides strong control of type 1 error without requiring prespecification of the list of possible subgroups or of the decision rule for selecting among them. Nevertheless, for regulatory submissions it is recommended that the subgroups and decision rule be prespecified. The method is applied to a large cardiology trial in which the subgroups are prespecified and the decision rules for subgroup selection and sample size alteration are based on conditional power. It is shown by simulation that substantial gains in power can be attained if there is a subgroup by treatment interaction.Mesh:
Year: 2011 PMID: 21516572 DOI: 10.1080/10543406.2011.554129
Source DB: PubMed Journal: J Biopharm Stat ISSN: 1054-3406 Impact factor: 1.051